Active Research
-
A master protocol for a Phase 3, multicenter, open-label, long-term extension study to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease
Primary Investigator: Huang, MD, Clifton
IRB ID: 2021-008 (OPEN)
-
ABX464-107: A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
Primary Investigator: Huang, MD, Clifton
IRB ID: 2022-103 (OPEN)
-
CNTO1959PBCRD3007, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23) (Intervention Specific Appendix to Master Protocol PLATFORMPBCRD3001/I6T-MC-PIBD)
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-064 (OPEN)
-
I6T-MC-AMAY, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (ISA Title: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab inPediatric Crohn’s Disease)
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-065 (OPEN)
-
KiteLock™ RCT: SAFETY AND EFFECTIVENESS OF 4% TETRASODIUM ETHYLENEDIAMINETETRAACETIC ACID CATHETER LOCK SOLUTION IN PREVENTING CENTRAL VENOUS CATHETER OCCLUSIONS IN CHILDREN WITH INTESTINAL FAILURE: A RANDOMIZED CONTROLLED TRIAL
Primary Investigator: Osuntokun MD, Bankole Oluseyi
IRB ID: 2024-035 (OPEN)
-
PLATFORMPBCRD3001/I6T-MC-PIBD, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-063 (OPEN)
-
Using data from a network of patients, families, clinicians, researchers and health care organizations to improve care and outcomes for children, adolescents and young adults with Inflammatory Bowel Disease
Primary Investigator: Ogunmola MD, Nick
IRB ID: 2021-066 (OPEN)
-
Utility of RESPONDR® TNF, a laboratory developed diagnostic test, in a real-world inflammatory bowel disease population
Primary Investigator: Huang, MD, Clifton
IRB ID: Prometheus Laboratories_RESPONDR 24IBD02_Huang (OPEN)